<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291356</url>
  </required_header>
  <id_info>
    <org_study_id>KG2104940</org_study_id>
    <nct_id>NCT00291356</nct_id>
  </id_info>
  <brief_title>GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Repeat Dose Study to Compare the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 With GW869682 in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a study to compare the safety, blood concentrations, and effects of GSK189075,
      GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: side effects and relevant changes in blood pressure, heart rate and ECG measurements, blood and urine measurements, the amount of fluid taken in and excreted, and kidney function will be monitored over course of study.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount and percentage of glucose excreted in urine by kidneys. Effect of compounds on lipid metabolism analysed.</measure>
  </secondary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Non-Insulin-Dependent Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK189075 oral tablets</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW869682 oral tablets</intervention_name>
    <other_name>GSK189075 oral tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Type 2 diabetes.

          -  HbA1c (a measure of the average amount of sugar in blood over the last 2 or 3 months)
             levels are between 7.0 and 9.0.

          -  Taking 850mg or more per day metformin, but not taking any other diabetes medications.

          -  Must be medically able and willing to discontinue diabetic medications from at least 2
             weeks prior to first study dose until the last study assessment.

          -  Diabetic subjects who have not yet started taking diabetes medications or whose
             diabetes is controlled by diet alone may also be eligible to enroll if their HbA1c is
             within 7.5 to 9.0.

          -  Women may be eligible if they are post-menopausal or surgically sterile.

          -  If taking ACE inhibitors, beta-blockers, calcium channel blockers, or statin type
             drugs, you may be eligible if your dose has been stable for at least 30 days prior to
             the start of the clinical trial.

        Exclusion criteria:

          -  Using illicit drugs, or have antibodies to hepatitis B, hepatitis C, or HIV.

          -  Have any major health problems other than type 2 diabetes.

          -  Require insulin therapy or oral antidiabetic medication other than metformin.

          -  Subjects who have had a urinary tract infection within 4 weeks of the start of the
             study or who have kidney disease.

          -  Subjects with either low or high blood pressure.

          -  Men who are unwilling to abstain from intercourse, or use a condom with a pregnant or
             nursing female, or who are unwilling to use a condom with another form of
             contraception with a female who could become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2006</study_first_submitted>
  <study_first_submitted_qc>February 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>sodium dependent glucose transporter</keyword>
  <keyword>SGLT2</keyword>
  <keyword>GSK189075</keyword>
  <keyword>GSK189074</keyword>
  <keyword>SGLT1</keyword>
  <keyword>GW869683</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 13, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 18, 2017</submitted>
    <returned>February 2, 2018</returned>
    <submitted>February 13, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

